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DNA vaccinations against fish viral diseases as IHNV at commercial level in Canada against VHSV at experimental
level are both success stories. DNA vaccination strategies against many other viral diseases have, however, not yet
yielded sufficient results in terms of protection. There is an obvious need to combat many other viral diseases
within aquaculture where inactivated vaccines fail. There are many explanations to why DNA vaccine strategies
against other viral diseases fail to induce protective immune responses in fish. These obstacles include: 1) too low
immunogenicity of the transgene, 2) too low expression of the transgene that is supposed to induce protection, 3)
suboptimal immune responses, and 4) too high degradation rate of the delivered plasmid DNA. There are also
uncertainties with regard distribution and degradation of DNA vaccines that may have implications for safety and
regulatory requirements that need to be clarified. By combining plasmid DNA with different kind of adjuvants one
can increase the immunogenicity of the transgene antigen – and perhaps increase the vaccine efficacy. By using
molecular adjuvants with or without in combination with targeting assemblies one may expect different responses
compared with naked DNA. This includes targeting of DNA vaccines to antigen presenting cells as a central factor
in improving their potencies and efficacies by means of encapsulating the DNA vaccine in certain carriers systems
that may increase transgene and MHC expression. This review will focus on DNA vaccine delivery, by the use of
biodegradable PLGA particles as vehicles for plasmid DNA mainly in fish.Table of contents
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There are quite a limited number of DNA vaccine strat-
egies that have been successful in giving significant pro-
tection against fish diseases. The excellent exceptions
are DNA vaccination against infectious hematopoietic
necrosis virus (IHNV) at commercial level and against
viral hemorrhagic septicemia virus (VHSV) at experi-
mental/small scale level [1]. A promising strategy to in-
crease the DNA vaccine efficacy, against other virall Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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gen presenting cells. Wang et al. [2] have presented an
overview on how DNA vaccines can be targeted to anti-
gen presenting cells (APC) and dendritic cells (DC)
using molecular assemblies with the resulting immune
responses. Another strategy is to encapsulate the DNA
vaccine in certain carriers with the intention to increase
transgene and MHC expression. There are many par-
ticulate carriers that have been explored to present and
target DNA vaccines to desired cells and tissues, one of
them being poly (D,L-lactic-co-glycolic)-acid (PLGA)
particles.
2. DNA vaccines and vaccination
The definition of DNA vaccination as provided by The
Norwegian Biotechnology Advisory Board [3] is “the
intentional transfer of genetic material (DNA or RNA)
to somatic cells for the purpose of influencing the im-
mune system”. This sets it slightly apart from gene ther-
apy, which in the same report is referred to as an
introduction of novel gene(s) for purposes other than in-
fluencing the immune system. The mechanism of a
DNA vaccine can in many ways be likened to that of a
virus, as it requires the same cellular machinery in order
to replicate and since it also triggers immune responses
normally seen with viral infections [4]. Unlike conven-
tional viral vaccines based on subunits or killed virus, a
DNA vaccine may conserve the structure and hence also
antigenicity of a transgenic antigen/protein [5].
3. Immune responses to DNA vaccination – mainly
in mice and birds
A vital attribute of DNA vaccines is the ability to in-
duce all three arms of adaptive immunity, namely;
helper T-cells, cytotoxic T cells (CTLs) and antibodies,
although they were initially investigated in the attempt
to find ways of delivering antigen to major histocom-
patibility complex (MHC) class I and induce T helper
1 (Th1) responses [6,7]. Professional APCs are the cells
that primarily contribute to the immune responses to
DNA vaccination. Direct transfection of DCs provides
the most efficient priming of naïve CTLs, and is per-
haps the major mechanism for priming of these cells
[8]. APCs are also able to take up exogenous antigens
and process them for presentation by either MHC class
II, or MHC class I following transfer of the antigen to
the cytosol (cross-priming) [9]. These responses are
vital in the cellular immune response following DNA
vaccination. The expression of reporter genes is not
only higher in fish, but also seems to have a longer
duration. Transgene expression has been detected at
the injection site as long as two years after injection of
glass catfish (Kryptopterus bicirrhus) [10], and Tonheim
et al. detected both supercoiled (sc) DNA and luciferaseexpression at the injection site 535 days after intramuscu-
lar injection of Atlantic salmon (Salmo salar L.) with
pDNA [11].
The immunogenicity of DNA vaccines stems not only
from the expression of the GOI, but also from properties
of the plasmid vectors themselves. The ability of foreign
nucleic acids to induce interferons (IFNs) in mouse fi-
broblasts was discovered by two independent research
groups as early as in 1963 [12]. The most studied pDNA
property in terms of possible adjuvant effects is CpG
motifs, regions in the DNA where a cytosine nucleotide
occurs next to a guanine nucleotide and the two are
linked by a phosphodiester bond. In vertebrates these se-
quences are highly methylated, whereas they show a
much lower methylation frequency in viral and bacterial
DNA (such as pDNA). These CpG motifs can act as
pathogen-associated molecular pattern molecules (PAMPs)
and are recognized as danger signals by the vertebrate im-
mune system, resulting in a release of cytokines, macro-
phage activation, a differentiation of Th1 effector cells as
well as B-cell proliferation and secretion of antibodies [13].
Plasmid DNA containing optimized CpG content may be
likely used in DNA vaccine strategies.
4. DNA vaccination against novirhabdoviruses
The first DNA vaccination of fish took place in 1996,
when Anderson et al. immunized rainbow trout (Onch-
orhyncus mykiss) against IHNV [14]. Since then several
trials have been performed for a wide variety of fish spe-
cies and pathogens and in 2005 a vaccine against IHNV
infection in salmonids (Apex-IHN®, Novartis Animal
Health) was also one of the first DNA vaccine ever to be
cleared for marketing (by the Canadian Food Inspection
Agency). In 1999 the injection of Atlantic salmon with
pCMV4-G (plasmid-encoded glycoprotein) from a rainbow
trout IHNV isolate induced significant protection against
challenges with IHNV, even though the salmon were much
larger than the rainbow trout in previous challenge studies
[15]. DNA vaccination of fish has been shown to induce
both innate and adaptive immune responses similar to
what is seen in mammalian species, and seems especially
efficient against novirhabdoviruses (like VHSV and IHNV).
These are simple RNA viruses with either five or six genes
and a single viral surface protein (glycoprotein, or G pro-
tein) that acts as the protective antigen [16].
In rainbow trout an immunization against VHSV en-
ables the induction of cell-mediated immune responses
encompassing both CTLs and natural killer (NK) cells and
has also been shown to significantly reduce the replication
of virus during challenge [17]. Interestingly, when Cuesta
et al. looked at the innate and adaptive responses in vacci-
nated and control fish after challenge, they found the
highest increase in vaccinated fish to be that of innate im-
mune responses [18]. Lorenzen et al. [19] have also
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antiviral defense, wherein rainbow trout were subjected to
VHSV challenge following vaccination with pIHN-G
(plasmid-encoded IHNV glycoprotein). Whereas pro-
tection at late stages of the challenge could only be
conferred by previous immunization with pVHS-G, the
two vaccines induced similar levels of immune re-
sponses and protection during the first week following
challenge.
In conclusion, anti novirhabdovirus response governed
by DNA vaccines relies much on the immunogenicity of
the G-protein resulting in long-lasting protection medi-
ated by cellular and humoral responses. In addition, there
is an innate and specific response following DNA vaccin-
ation that may be protective in a short-term perspective.
Other RNA viruses, or the larger DNA viruses, often
offer more difficulty in identifying a protective antigen,Table 1 Experimental DNA vaccines and their protection in fi
Pathogen Gene inserted Host
IHNV IHNV-G plus suicidal gene Rainbow trout
IHNV IHNV-G; different genogroups Rainbow trout
IHNV IHNV-G Rainbow trout





IPNV VP2; Segment A of TA strain Atlantic salmon
SAV E1 and E2 Atlantic salmon
Megalocytivirus 86-residue VP Turbot (Scophtha
maximus)
Edwardsiella tarda Eta6-FliC chimeric protein Japanese flounde
(Paralichthys oliva
E. tarda D15-like surface antigen Japanese flounde
E. tarda Eta2 Japanese flounde
Streptococcus iniae sagF, sagG and sagI Japanese flounde
S. iniae Sia10 delivered by E. tarda Japanese flounde
Vibrio harveyi FlaA Yellow grouper
(Epinephelus awoa
V. harveyi DegQ or/and Vhp1 Japanese flounde
V. alginolyticus FlaA Red snapper (Lutj
campechanus)
S. iniae and V.
anguillarum
Sia10 and/or OmpU Turbot
Flavobacterium
psychrophilum
Hsp60, hsp70 Rainbow trout
Cryptocaryon irritans iAg Orange spotted g
(E. coioides)
Cryptobia salmocitica Metalloprotease Atlantic salmon a
rainbow trout
Ichthyophthrius multifiliis Immunobilization antigens
and cystein protease
Rainbow troutalthough viral surface protein genes are almost always
chosen for DNA vaccines [2]. Some pathogens, such as
infectious pancreatic necrosis virus (IPNV), primarily
cause disease in fry. Whereas vaccination by injection is
highly impractical at this stage [20], the vaccination of
post-smolts has been shown to induce protection upon
challenge [21]. Good protection did, however, require
the use of plasmids encoding all the large poly-proteins
of the IPNV.
5. Recent DNA vaccination laboratory trials
DNA vaccines and their effects against several viral and
bacterial diseases in fish have been reviewed by Tonheim
et al. [22], Kurath [23], Redding and Weiner [24], and
Gomez-Casado et al. [25]. Since these reviews were pub-
lished, several new results using DNA vaccine strategies
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tion against bacteria and parasites – but not against all.
Bacteria and parasites may express and harbor numer-
ous different antigens dependent on their life cycle, this
make a DNA vaccination strategy more complicated.
There are developed “traditional” oil adjuvanted vaccines
against a number of bacterial diseases, where the strat-
egies may be quite efficient preventing infection and dis-
ease. This is in contrast to some parasitic infections/
attachment such as sea lice - where no immune prophy-
laxis exists at present at an industrial scale.
6. Administration and distribution of DNA
vaccines
6.1. Intramuscular injection
Intramuscular injection is widely applied for pDNA de-
livery in fish and generally results in strong expressions
of transgene at the injection site [22]. Studies in mice
have found the dispersion of pDNA immediately follow-
ing intramuscular injection to take place primarily be-
tween the muscle body and epimysium (connective
tissue that enclosing the entire muscle). Myocytes and
mononuclear cells take up pDNA after administration
[22], but despite a rapid initiation of uptake the subse-
quent uptake is slow and cells along the muscle fibers
have been shown to be transfected over a period of
hours following injection. With very small fish this initial
dispersion of a vaccine might be enough to ensure the
perfusion of intact pDNA to more distant tissues, while
in large fish the injected volume will mainly rest along
the needle trajectory [22]. The transportation of pDNA
to and from blood to other tissues has been reported for
various fish species [22]. Plasmids have been recovered
from sites such as liver, spleen, head-kidney, heart and
intestine for some time after injection, but mainly persist
at the site of injection. Degradation of the pDNA starts
within five minutes following injection of mice, with as
much as 95-99% of the initial pDNA amount degraded
within 90 min [22]. The rate of degradation in the tissue
of cold-water fish remains to be determined. The extent
of histopathological changes at the injection site fol-
lowing intramuscular DNA delivery in fish appear to
increase with an increase in vaccination dose [46], but
vaccination will generally induce only moderate local
tissue damage in form of degeneration of myocytes,
hemorrhages and a transient influx of inflammatory
cells [20].
6.2. Other routes of delivery
Other routes of pDNA administration that have been in-
vestigated in fish are intravenous, intraperitoneal, oral
delivery, and particle bombardment [1,21]. Accumula-
tion of naked pDNA took place primarily in the heart,
kidney and liver following intravenous administration[22], whereas oral delivery resulted in a recovery of
DNA fragments from the pyloric region, kidney, spleen
and liver – assessed by revers-transcription polymerase
chain reaction (RT-PCR) [28].
7. Uptake of plasmid DNA in fish and mammalian
species
A wide variety of mammalian cell types has been shown
to take up pDNA – reviewed by Budker et al. [47], but
so far uptake in fish has only been reported for myo-
cytes, head kidney macrophages and endocardial endo-
thelial cells (EECs) [22]. The exact mechanisms by which
myocytes take up pDNA remains to be determined, but
several suggestions have been made [48]. It was previously
theorized that direct injections caused temporary mem-
brane disruptions and/or pores that allowed for the entry
of pDNA [5], but studies have shown that such disrup-
tions in fact work to abolish transfection [12].
Several PPRs have been shown to bind nucleic acids
including plasmid DNA, reviewed by Desmet et al. [49].
Of the number of cell-surface receptors investigated in
terms of DNA binding and uptake, scavenger receptors
(SRs) in particular have been a subject of interest. These
receptors comprise a broad family of membrane proteins
capable of binding a wide range of anionic ligands and
are present on several different cell types [50]. The up-
take of pDNA by SRs has been demonstrated in Atlantic
cod (Gadus morhua) atrial EECs [51], but although the
SRs may bind DNA they appear not to be essential for
the immunostimulatory activity of CpG DNA [52]. This
indicates that SRs activity may be essential for the trans-
gene expression – as they may bind and facilitate deg-
radation of high amount of plasmid DNA before
expression occurs.
8. Factors influencing transfection and transgene
expression
Nucleic acids have poor intrinsic transfection efficiency
due to their large size and negative charge [53]. The pro-
cesses of gene transcription and translation are carried
out by the cell’s own machinery, and may be influenced
by a variety of factors such as pDNA vector design,
pDNA concentrations, administration volumes, age and
size of the fish, water temperatures and method as well
as route of administration.
It has been well documented that the DNA topoform
has a strong influence on the efficiency of transfection
[54]. Supercoiled DNA is frequently reported as the
most potent topoform followed by open circular (oc)
forms, whereas linearization of the DNA has been
shown to nearly abolish the expression of transgene and
linearized pDNA. The choice of promoter also has a
profound influence on the level of transgene expression
[55] and the cytomegalovirus (CMV) promoter has often
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the CMV promoter is the most commonly applied in
gene transfection studies and its potency has been
demonstrated also in fish [5]. The use of an intron and
poly-adenylation (termination) signals further improves
expression [55].
Despite the inherent adjuvant effects of DNA vaccines,
it has been shown that immune responses triggered by
DNA vaccination may in fact limit the duration of trans-
gene expression [55]. The lack of anti-Luc antibodies
means that both levels and duration of expression are
commonly higher in studies applying luciferase com-
pared to more immunogenic antigens, and immune re-
sponses have only been observed with the application of
large pDNA doses and potent adjuvants such as Freund´
s complete adjuvant (FCA) [56]. A co-administration of
vectors encoding Luc and immunogenic proteins (β-gal,
G protein) decreases both the strength and duration of
luciferase expression, as the initiated antigen specific
cytotoxic responses work to eliminate transfected cells
expressing the transgenic protein [56]. The stimulation
of PRRs may also induce responses that can be detri-
mental to transgene expression. The hallmark cytokines
of the inflammatory response, TNF-α and IL-1β, have
both been shown to inhibit transgene expression in vitro
and in vivo [57], as have the Th1 associated cytokines
IFN-γ and IFN-α [58]. Levels of inhibition have in fact
been shown to correlate with the levels of CpG-induced
cytokines, and synergistic effects were also observed.
The inhibitory effect takes place at the mRNA (post-
transcriptional) level, hence not causing vector degrad-
ation, inhibition of total cellular protein synthesis or
elimination of infected/transfected cells [58].
Whereas intramuscular injection is widely acknowl-
edged as the superior method of administration to
achieve high levels of transgene expression [1], the result
still depends on factors such as dose, volume and fish
size and age [59]. Transgene expression has been found
to be higher in young and growing fish [5], and small
fish sizes appear to favor not only the distribution of
pDNA throughout tissue but the distribution of trans-
gene expression as well [5]. For example expression of
luciferase in thymus, gills, spleen and kidney has been
reported for small fish (< 5 g), although the highest ex-
pression is consistently detected at the site of injection
in myocytes, infiltrating cells and epithelial cells lining
small capillaries [20,60].
The first reporter gene study in fish indicated the ex-
istence of a maximum above where there would be no
further increase in expression [60]. This observation is
supported by later findings in zebra fish (Danio rerio)
and rainbow trout [5], and there are indications that ex-
cessive DNA concentrations may actually reduce trans-
gene expression [21]. The injection of large volumesmight contribute to a spatial distribution by creating
temporary gaps between fibers [61], which appears to in-
duce higher expression as well as reduce the variations
commonly observed in in vivo transfection studies [5]. A
pre-injection of an isotonic solution created the same ef-
fect, and lead to both higher and more equal transgene
expression among individuals after DNA injection [61].
9. Advantages, disadvantages and challenges of
DNA vaccines
The potency of DNA vaccines for inducing the different
branches of both innate and adaptive immunity has
already been described. DNA vaccines also show high ef-
ficiency when given at early life stages [62], and provide
the benefit of inducing protective immunity over a wide
span of temperatures [63].
The advantages of DNA vaccination still stretch beyond
merely the immunological capacities. Looking at the con-
cept from a manufacturer or/and investor’s standpoint,
DNA vaccines are relatively inexpensive and easy to pro-
duce. The processes required for production are identical
for all DNA vaccines, and the ease of cloning also enables
rapid modifications in a way that is generally not obtain-
able with conventional vaccine preparations [60].
Potential side effects include e.g. risk of autoimmunity,
immune tolerance against the expressed antigen, too
high CTL response resulting in myositis, chromosomal
integration, injection site inflammation and tissue de-
struction [1,64].
10. Application of molecular adjuvants to increase
transgene immunogenicity
To increase immunogenicity of a given DNA vaccine
one may consider optimization by including co-injected
adjuvant, either being traditional aluminum salts, polysac-
charides (e.g. zymosan, glucans, chitosan), different lipo-
somes, synthetic polymers and TLR agonists. Moreover,
plasmid encoded cytokine adjuvants may also be one
approach to increase the immunogenicity. IL-2, IFN-γ,
IL-12, GM-CSF and IL-15 have been shown to modu-
late immune responses when co-encoded by the DNA
vaccine [65]. One may also apply the concept of im-
mune modulating effects chemokines, transcription
factors and/or co-stimulatory factors assembled into
the plasmid vectors. Using fish models, only one report
on the use of cytokine adjuvants encoded by the same
plasmid as the expression plasmid has been published.
Caipang et al. used Japanese flounder interferon regu-
latory factor-1 (IRF-1) cloned into a plasmid DNA vec-
tor containing the major capsid protein gene of sea
bream iridovirus. The antibody levels of fish injected
with this vaccine were not significant higher with the
control plasmid without IRF-1 gene [66]. Unfortu-
nately, no experimental virus challenge was carried out
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tency and efficacy of poor performing DNA vaccines
one should explore strategies such as inclusion of mo-
lecular adjuvants perhaps in combination with target-
ing carrier systems such as nano- and microparticles.
Although transfection levels are often low, studies have
demonstrated a persistence of transgene expression at
the injection site that might coincide with a time when
the fish would normally be ready for slaughter [67].
There have been experiments with suicidal DNA vac-
cines for fish, where the plasmid vector includes a pro-
tein to induce apoptosis after an immune response has
been triggered [26].
11. PLGA particles as carrier systems for DNA
vaccines – focus on fish
Besides the proven efficacy of G-protein expressing plas-
mids against novirhabdoviruses, there is an urgent need
to develop high performing vaccines against other viral
diseases. In this aspect, DNA vaccines delivered by sev-
eral kinds of particles may show promise. There is con-
siderable research being done on the application of
carrier systems and/or DNA-complexes to facilitate
higher levels of entry and reduce degradation, reviewed
by Saade et al. [65]. The potential of PLGA particles as
adjuvants and carriers for DNA vaccine delivery has re-
ceived considerable attention in mammalian studies [68].
In spite of this, reports on the use of PLGA particles for
DNA delivery to fish are nearly non-existent. In 2008,
Tian et al. were the first to report on the use of PLGA
microcapsules containing a plasmid vaccine for the oral
immunization of Japanese flounder against lymphocystis
disease virus (LCDV) [69]. Following immunization they
detected transgene expression in gills, intestine, spleen
and kidney from fish vaccinated with encapsulated
pDNA. The encapsulated pDNA also induced higher
levels of antibodies compared to control fish injected
with naked pDNA. Tian and Yu later demonstrated a
significant increase in resistance to LCDV infection after
oral administration of a pDNA vaccine encapsulated into
PLGA nanoparticles [70]. Finally, the last study so far re-
ported was by Adomako et al., who used PLGA nano-
particles incorporated into feed for oral delivery of a
DNA vaccine against IHNV to rainbow trout [28]. They
found that particles were mostly taken up in the poster-
ior gut, but that a significant number of fish that showed
uptake in gastrointestinal epithelial cells did not demon-
strate detectable levels of transgene expression. Al-
though antibody responses could be detected in fish
given high doses of pDNA, the RPS at a six weeks post-
vaccination challenge was still only 22%. No VHSV/
IHNV DNA vaccine trials using nano- or micro-particle
vehicles have been carried out so far. It would have been
very interesting to compare the vaccine efficacy of nakedplasmid encoding for VHSV and IHNV G-protein to
corresponding particle delivered vaccines.
The exploitation of PLGA encapsulated DNA vaccines
in fish is new, currently there are no information
whether this strategy is a way to go to increase efficacy
of DNA vaccines for fish. There are, however, indications
that pDNA encapsulated in PLGA nanoparticles induce
a antiviral immune response in salmon - at a higher level
than what is achieved with only pDNA [71].
12. Issues of making DNA encapsulated PLGA
particles
The w1/o/w2 method described previously is fre-
quently used for the encapsulation of pDNA into
PLGA particles, but results are highly variable with re-
gard to encapsulation efficiency and loading as well as
DNA degradation and release. The hydrophilic nature
of DNA complicates the process of encapsulation as it
increases the risk of plasmid diffusion into the w2
phase during solvent evaporation [72], and the encap-
sulation process also offers multiple challenges in
terms of preservation of bioactivity – i.e. keeping the
supercoiled DNA topoform intact.
Among the factors known to affect the integrity of the
pDNA to be encapsulated are the polymer composition
and molecular weight (Mw), shear force, preparation tem-
peratures, solvents and the concentration and Mw of the
applied stabilizer [73]. In general, polymers with a high
Mw also result in the highest encapsulation efficiencies
and lower the burst release of plasmid DNA [73].
13. Transgene expression and immune responses
by PLGA-encapsulated pDNA
Encapsulated DNA has been shown to be more potent
than naked DNA at mediating transgene expression
in vitro in a variety of mammalian cells types [74]. How-
ever, in vivo studies report on a superiority of naked
DNA in eliciting transgene expression not only com-
pared to PLGA particles, but also to other formulated
DNA vaccines as well [74].
Small particles (< 100 nm) are often shown to be inter-
nalized more rapidly, and also show the highest transfec-
tion efficiencies [75].
The adsorption of plasmid DNA onto the surface of
PLGA particles, rather than encapsulation, has been re-
ported to result in a higher transgene expression, but
the expression declined more rapidly [48].
In addition to the pro-inflammatory cytokines induced
by empty PLGA nano- and micro-particles (IL-1β and
TNF-α) [76], the use of different particle sizes might in-
fluence the resulting cytokine profile after administration
of encapsulated or particle-bound CpG DNA [77]. In
addition to pro-inflammatory cytokines, nanoparticles
have been shown to also enable an induction of antiviral
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capsulation of pDNA encoding antigens has also been
shown to elicit CTL-responses, even with pDNA-amounts
that elicited no such responses after naked administration
[77]. Moreover, encapsulated pDNA also enhanced the
total antibody response at high doses, while inducing a
more rapid and complete sero-conversion when lower
doses were applied [78].
The injection of PLG microspheres into muscle has
been shown to result in a foreign body response, with a
large influx of different inflammatory cells that appear
largely related to microspheres especially at later time-
points [79]. These infiltrating cells were also the ones
that were primarily transfected, an observation similar to
that found in another study [80].
14. Other particles in vaccine delivery to fish
The extensive use of PLGA as vaccine delivery vehicles
can largely be attributed to their high biocompatibility
as well as the ease with which the particles can be pre-
pared. There are other means to increase the level of
transgene expression that may increase vaccine efficacy,
given that the transgenes produced display fair immuno-
genic properties, by using tailored particle systems – as
outlined by Nguyen et al. [73]. Other particles have also
been investigated as carrier systems for vaccination of
fish (Table 2), either on their own or in combination.
15. Current challenges in the use of PLGA
particles as carriers/adjuvants
Despite a growing number of optimistic reports on the
adjuvant/carrier properties of PLGA particles, there are
still many hindrances to be overcome. One of these is
the preparation method, where different drugs/vaccines
require different conditions. While some compounds are
easily encapsulated, others – like DNA vaccines – are
more difficult to encapsulate in an efficient manner. Low
encapsulation efficiencies not only result in low antigen
loading, but also mean that a large amount of drug/Table 2 Compounds tested as adjuvants and gene vaccine de
date
Particles Carrier molecule(s)
Alginate ß(1,4)-D-mannuronic and α(1,4)-L-guluronic
acid residues
Chitosan ß(1,4)-D-glucosamine and N-acetyl-D-glucosam
copolymer
Liposomes Artificial lipid bilayer vesicles
Polycaprolactone Biodegradable, synthetic polymer
Calcium phosphate Inorganic, biodegradable and biocompatible
materialvaccine goes to waste during particle preparation. The
detrimental effects that encapsulation may have on cer-
tain antigens such as pDNA are also major limiting fac-
tors at the moment, and need to be resolved. Particle
preparation is also low-scale work as of yet, with consid-
erable effort to be made before the process is optimized
on a large scale suitable for mass-production.
16. Concerns regarding PLGA nano- and
micro-particles
Any construct/compound, when brought down to sub-
micron sizes, will exhibit new and potentially harmful
characteristics [89]. The small size means they can inter-
act with biological membranes in an entirely new way,
thus inducing responses not seen with larger constructs.
As with all new applications it takes time to fully survey
the potential side effects. In vitro studies using PLGA
nano- and micro-particles have so far not revealed any
toxic effects, even at large doses [90]. The various concerns
regarding the use of PLGA particles in aquaculture vac-
cines have recently been reviewed by Nielsen et al. [91].
17. Safety and regulatory aspects by DNA
vaccines
Safety aspects include potential effects on the vaccinated
animals, the environment and the consumer [1,64,92].
Other safety issues include potential shed of the vaccine
to the environment from the vaccinated animal and by
predatory animals [93]. Human safety does also, al-
though with low probability, include potential effects by
self-injection by vaccinators. These safety aspects need
to be taken into consideration by relevant authorities
when safety aspects are to be documented.
The Canadian Food Inspection Agency (CFIA) that
gives authority to the Veterinary Biologics Section (VBS)
of the Animal Health and Production Division (AHPD)
approved the IHNV DNA vaccine for commercial use in
Canada in 2005 [94]. Five aspects were taken into con-
sideration before the vaccine was approved: (i) publiclivery systems to fish species, published from 2007 to
Assembly Species
Encapsulation Japanese flounder [81]
ine Encapsulation Nile tilapia (Oreochromis niloticus) [82]
Japanese flounder [83]
Asian sea bass (Lates calcifer) [84]
Turbot [85]
Encapsulation Kelp grouper (E. bruneus) [86]
Coating Indian major carp (Labeo rohito) [87]
Coating Indian major carp [88]
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mental concerns, (iii) risk-benefit, (iv) feasibility of pro-
ducing the vaccine at a scale and cost appropriate for
the fish industry, and (v) intellectual property issues
[91]. At present there has not been approved any DNA
vaccine to be used in aquaculture in Europe. To obtain
marketing authorization within Europe, a new veterinary
medicine has to meet the criteria and requirements of
the EU pharmaceutical legislation for both medical and
veterinary applications. To achieve a marketing applica-
tion a MAA (marketing authorization application) has to
be submitted to the European Medicines Agency (EMA).
The EMA has drafted guidelines for the veterinary use
of DNA vaccines [95]. The European guidelines include
several aspects to be considered in order to conduct a
risk assessment of DNA vaccines. This includes i) the
possibility of pDNA integrating into the chromosome, ii)
concerns about possible adverse effects on the immune
system, iii) risks posed by the additional use of genes en-
coding cytokines or co-stimulatory molecules or iv) un-
desirable biological activity by the expressed antigen
itself. At present there are work undertaken within EMA
with the intention to revise and update the guidance for
DNA vaccines and the goal is to provide a specific guid-
ance document [96]. This work is especially concerned
to the use of DNA vaccines to humans and if the out-
come will have influence on the veterinary use of DNA
vaccines is therefore uncertain. The guidelines prepared
by the FDA (US) points to some of the same areas as in
EU, and recommends that safety testing should include
tests on vaccine immunogenicity, effects from cytokines
and other immunomodulatory genes, autoimmunity,
local reactogenicity and systemic toxicity and studies of
bio-distribution, persistence and integration [97].
The issue of plasmid persistence and chromosomal in-
tegration of DNA vaccine is of relevance for both safety
and policy [92,93]. Norwegian authorities may for ex-
ample, due to uncertainties with regard to whether DNA
vaccines persist degradation in tissues and organs label
DNA vaccinated fish as a GMO [98]. If a DNA vacci-
nated animal is considered to be a GMO the producers
has also to meet the requirements of the EU environ-
mental legislation on the deliberate release of GMOs
(Directive 2001/18/EC). The objective of an environ-
mental risk assessment (ERA) in accordance with Direct-
ive 2001/18/EC is to identify and assess on a case-by-case
basis the potential harmful effects of a GMO for humans,
animals (domestic and wildlife), plants, microorganisms
and the environment. The EMA has developed two spe-
cific guidelines for the preparation of ERA to facilitate
adoptions of the requirements and the methodology of
the Directive to GMO-containing medical products. Al-
though these guidelines have mainly been used for MAA
of GM vaccines, they may provide necessary informationand procedures that can also be used to perform ERA for
DNA vaccines and vaccinated animals.
The process of obtaining a market authorization for a
new fish vaccine is a both time consuming and expen-
sive. To overcome some of the legal uncertainties there
is a need to assess potential consequences on a case-by-
case basis and to be aware of that a number of factors
such as the inserted gene, other gene inserts of the
pDNA, injection site and amount of vaccine injected are
of importance. Safety and regulatory uncertainties are
related to distribution and degradation of the DNA after
injection and includes that there is a need of research on
the (i) the stability of the DNA vaccine, (ii) plasmid per-
sistence, (iii) unintended immunological impacts, and
(iv) potential for integration of the pDNA into the
chromosome of the recipient organism [93]. These un-
certainties are also of relevance for consumer acceptance
and the markets confidence in safety.
The GMO issues may only be of concern for countries
that have specific GMO legislation and that demands
that GMOs and products thereof need to be labeled. In
USA and Canada there are no requirements for label-
ing of food containing GMOs, and they do not have
specific GMO legislation. In Europe due to the uncer-
tainties with regard to the persistence of a DNA vac-
cine, the vaccinated fish may need to be labeled as a
GMO. For example European countries that employ
restrictions on GMO may not import the DNA vacci-
nated fish, and if the fish need to be labeled as a GMO
this will have an influence on consumer willingness to
buy it. Ultimately may these uncertainties prevent the
use of DNA vaccines [92].18. Conclusions
There is a crucial need to increase efficacy of DNA vac-
cines against persistent and hard-to-combat viral infec-
tions, this can be met by: (i) Application of vaccine carriers
to increase the uptake in antigen presenting cells –
followed by enhanced presentation of transgene peptides/
antigens, (ii) Use of nano-scale particles to increase the
level of cross presentation by such cells – this may also be
beneficial to produce antibody response as well as cell me-
diated immunity, and (iii) Employing additional adjuvants
such as TLR ligands, other than RNA and/or DNA, ligands
to boost the response considerably. Safety and regulatory
uncertainties are related to distribution and degradation of
the DNA after injection and more effort needs to be put
into gaining understanding of the mechanisms of pDNA
uptake, from the moment of administration until the stage
of transcription and translation in the nucleus.19. Competing interests
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